Bilacidin $30 - $60M each/yr. Once we get into P3 and can establish even more comparisons who knows. I was even just researching Taflaro a bit. Some of these competitions have side effects that Brilacidin doesn't. That, imo slides us up the scale towards the high end. Also, some of the competition is heading towards generics which imo may or may not add to the side effects making them even less desirable. We've seen some of the other comparisons mentioned here and there including dapto.

We have them beat. Big time.

imo

1.10 is (explicative) ridiculous.